Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 26.
doi: 10.1007/s10620-025-09139-z. Online ahead of print.

Selective Internal Radiation Therapy Combined with Immune Checkpoint Inhibitors in the Treatment of Hepatocellular Carcinoma: A Systematic Review and Single-Arm Meta-Analysis

Miriana Mariussi  1 , Mariano Gallo Ruelas  2 , Laura Costa de Oliveira Lima  3 , Felipe Furtado Leite  4 , Marcela Juliano Silva Cunha  4 , Leonardo Guedes Moreira Valle  4 , Breno Boueri Affonso  4 , Francisco Leonardo Galastri  4 , Pedro Luiz Serrano Uson Junior  5 , Lilian Yuri Itaya Yamaga  6 , Felipe Nasser  4 , Rodrigo Gobbo Garcia  4
Affiliations

Selective Internal Radiation Therapy Combined with Immune Checkpoint Inhibitors in the Treatment of Hepatocellular Carcinoma: A Systematic Review and Single-Arm Meta-Analysis

Miriana Mariussi et al. Dig Dis Sci. .

Abstract

Purpose: The aim of this systematic review and meta-analysis is to determine the efficacy and safety of selective internal radiation therapy (SIRT) using yttrium-90 (Y-90) combined with immune checkpoint inhibitors (ICIs) in the treatment of hepatocellular carcinoma (HCC).

Materials and methods: We systematically searched Embase, Cochrane Central Register of Controlled Trials, Pubmed/Medline, and Web of Science from inception to September 10th of 2024 for studies published with the following medical subject heading terms: "selective internal radiation therapy", "immunotherapy", "immune checkpoint inhibitors", and "hepatocellular carcinoma". In addition, the references of included studies and systematic reviews were evaluated for additional studies. The outcomes of interest were median overall survival (mOS), median progression-free survival (mPFS), median time to tumor progression (mTTP), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). A subgroup analysis of ORR was conducted based on patients' BCLC staging, along with a comparison between studies that initiated ICIs prior to SIRT and those that administered SIRT before ICIs.

Results: The review included seven studies, consisting of four clinical trials and three retrospective cohort studies, with a total of 184 patients. The pooled analysis demonstrated an ORR of 58.08% (95% CI: 39.07-77.09) and a DCR of 85.03% (95% CI: 76.23-93.83). The pooled mTTP, mPFS and mOS resulted in 7.17 months (95% CI: 5.05-9.29), 7.12 months (95% CI: 5.29-8.95) and 20.43 months (95% IC: 17.58-23.29), respectively. The subgroup analysis of ORR according to the patients' BCLC staging, including BCLC-B and BCLC-C, resulted in a pooled ORR of 75.71% (95% CI: 57.71-93.71) and 60.86% (95% CI: 37.10-84.63), respectively, with no significant difference between groups (p = 0.33). There was no significant difference in the subgroup analysis between studies that initiated ICIs prior to SIRT and those that administered SIRT before starting ICIs. During treatment 53.48% (95% CI: 25.89-80.06) of the patients experienced grades 1-2 adverse events, and 16.17% (95% CI: 6.52-28.52) experienced grades 3-4 adverse events. One patient in the analysis experienced a grade 5 adverse event.

Conclusion: The findings of this systematic review and meta-analysis indicate that the combination of SIRT using Y-90 with ICIs may offer a durable treatment response and promising efficacy with an acceptable safety profile for HCC. However, results should be interpreted with caution due to the limited number of published studies and the need for further investigation regarding patient selection, treatment sequence, efficacy, and safety.

Keywords: Hepatocellular carcinoma; Immune checkpoint inhibitors; Immunotherapy; Interventional oncology; Selective internal radiation therapy.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflicts of interest: The authors declare no competing interests.

Similar articles

See all similar articles

References

    1. Petrick JL, Florio AA, Znaor A et al. International trends in hepatocellular carcinoma incidence, 1978–2012. Int. J. Cancer 2020;147:317–330. https://doi.org/10.1002/ijc.32723 . - DOI - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 2018;68:394–424. https://doi.org/10.3322/caac.21492 . - DOI - PubMed
    1. Marrero JA, Kulik LM, Sirlin CB et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatol. Baltim. Md 2018;68:723–750. https://doi.org/10.1002/hep.29913 . - DOI
    1. Reig M, Forner A, Rimola J et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J. Hepatol. 2022;76:681–693. https://doi.org/10.1016/j.jhep.2021.11.018 . - DOI - PubMed
    1. Daniele B, Annunziata M, Barletta E, Tinessa V, Di Maio M. Cancer of the Liver Italian Program (CLIP) score for staging hepatocellular carcinoma. Hepatol. Res. 2007;37:S206–S209. https://doi.org/10.1111/j.1872-034X.2007.00186.x . - DOI - PubMed

LinkOut - more resources